<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008081</url>
  </required_header>
  <id_info>
    <org_study_id>S64324</org_study_id>
    <nct_id>NCT05008081</nct_id>
  </id_info>
  <brief_title>The CATALINA Study</brief_title>
  <official_title>A Pan-European Prospective Interventional Cohort Study in Patients Hospitalized With Acute COPD Exacerbations With Longitudinal Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wim Janssens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Respiratory Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CATALINA study is a prospective interventional cohort study embedded within CICERO&#xD;
      (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical&#xD;
      Research Collaboration), designed to collect standardised, longitudinal clinical data and&#xD;
      biological samples in 20 pan-European centres.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial objective is to recruit 1000 patients hospitalised for an acute COPD exacerbation&#xD;
      by the end of CICERO's first lifecycle (3 years), from whom 1 year follow-up data and&#xD;
      biological samples will be collected. By doing so, CICERO aims to develop a comprehensive&#xD;
      European COPD patient data- and biobank phenotyped in relation to the exacerbation, to&#xD;
      support the development of future EU-wide clinical intervention trials in COPD for specific&#xD;
      patient subgroups, as well as new prognostication tools for COPD exacerbations.&#xD;
&#xD;
      The clinical data and biological samples will be obtained during 6 scheduled study visits,&#xD;
      during the hospitalization period of the index acute exacerbation as well as the outpatient&#xD;
      setting after hospital discharge; and 3 additional unscheduled study visits should the&#xD;
      patient be readmitted for respiratory reasons during study participation (i.e. first&#xD;
      readmission).&#xD;
&#xD;
        -  3 study visits will be scheduled during the hospitalization period of the index acute&#xD;
           exacerbation:&#xD;
&#xD;
             -  visit 1: within 24h of hospital admission, study inclusion (Day 1)&#xD;
&#xD;
             -  visit 2: at 72h after study inclusion (Day 3)&#xD;
&#xD;
             -  visit 3: at hospital discharge, at investigator's discretion (Day X)&#xD;
&#xD;
        -  3 study visits will be scheduled during the outpatient setting:&#xD;
&#xD;
             -  visit 4: at 3 months after study inclusion (Day 90)&#xD;
&#xD;
             -  visit 5: at 6 months after study inclusion (Day 180)&#xD;
&#xD;
             -  visit 6: at 12 months after study inclusion (Day 365)&#xD;
&#xD;
        -  The first hospital readmission for respiratory reasons during the patient's study&#xD;
           participation will undergo the same testing schedule as mandated during the&#xD;
           hospitalization period of the index event:&#xD;
&#xD;
             -  unscheduled visit 1: within 24h of first hospital readmission&#xD;
&#xD;
             -  unscheduled visit 2: within 72h of first hospital readmission&#xD;
&#xD;
             -  unscheduled visit 3: at hospital discharge for first hospital readmission&#xD;
&#xD;
      Resulting from CICERO's future lifecycles will be the continued expansion of the data- and&#xD;
      bio-bank, both in cohort size and duration of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Will be assessed during 1 year, on visits 2-6</time_frame>
    <description>A composite outcome measure defined as treatment intensification for respiratory reasons, step-up in hospital care or readmission for respiratory reasons, or all-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Readmission for a severe COPD exacerbation</measure>
    <time_frame>Will be assessed during 1 year, on visits 2-6</time_frame>
    <description>Readmission of the patient to the hospital for a severe COPD exacerbation during study participation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implementation of a Do Not Resuscitate (DNR) code</measure>
    <time_frame>Will be assessed during 1 year, on visits 2-6</time_frame>
    <description>Implementation of a DNR code (new or change) during study participation&#xD;
DNR 0: do not restrict therapy (i.e. explicit statement not to withhold any life-sustaining interventions)&#xD;
DNR 1: do not resuscitate, further specified as:&#xD;
DNR 1a: No CPR DNR 1b: No CPR + no intubation + NIV to be considered&#xD;
DNR 2: do not extend therapy (i.e. no CPR + no intubation + no NIV)&#xD;
DNR 3: discontinue therapy (i.e. no CPR + no intubation + no NIV + withdrawal of current treatment°)&#xD;
Abbreviations: CPR, cardiopulmonary resuscitation; NIV, non-invasive ventilation; °, treatment of disabling symptoms to be prioritised, however, no life-prolonging interventions are to be continued</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Admission to intensive care unit (ICU) for respiratory reasons</measure>
    <time_frame>Will be assessed during 1 year, on visits 2-6</time_frame>
    <description>Admission of the patient to ICU for respiratory reasons during study participation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Will be assessed during 1 year, on visits 2-6</time_frame>
    <description>Death from any cause during study participation</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease Exacerbation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood (serum/plasma)&#xD;
&#xD;
        -  Sputum&#xD;
&#xD;
        -  Nasopharygeal swab&#xD;
&#xD;
        -  Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COPD, hospitalized for an acute exacerbation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Established diagnosis of COPD by medical doctor (based on clinical history OR&#xD;
             pulmonary function test with an FEV1/FVC &lt; 0.7)&#xD;
&#xD;
          -  Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD)&#xD;
&#xD;
          -  Inclusion within 24 hours post hospital admission&#xD;
&#xD;
          -  Voluntary written informed consent of the participant or his/her representative&#xD;
             obtained prior to any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling or unable to comply with study procedures&#xD;
&#xD;
          -  Patients not requiring treatment with systemic corticosteroids, antibiotics or both as&#xD;
             a minimum therapy for the index AECOPD&#xD;
&#xD;
          -  Patients with a confirmed positive test result for COVID19, or those highly suspected&#xD;
             based on clinical examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ/KU Leuven - Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Bafadhel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford University - UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Vermeersch, PhD</last_name>
    <phone>016342284</phone>
    <phone_ext>+32</phone_ext>
    <email>kristina.vermeersch@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maylorie 't Lam</last_name>
    <phone>016341966</phone>
    <phone_ext>+32</phone_ext>
    <email>maylorie.tlam@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristina Vermeersch</last_name>
      <email>kristina.vermeersch@kuleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Maylorie 't Lam</last_name>
      <email>maylorie.tlam@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Wim Janssens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Régis Burgel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Régis Burgel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LungenClinic</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Henrik Watz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henrik Watz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre of Gießen &amp; Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Timm Greulich, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bernd Schmeck, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Timm Greulich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Contoli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Contoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Hospital</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Frits Franssen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frits Franssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Arturo Huerta Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arturo Huerta Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Lowie Vanfleteren, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lowie Vanfleteren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Neil Greening, MD</last_name>
    </contact>
    <investigator>
      <last_name>Neil Greening, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Quint, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jennifer Quint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchil Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sanjay Ramakrishnan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mona Bafadhel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32139591/</url>
    <description>ERJ Editorial - The CICERO (Collaboration In COPD ExaceRbatiOns) Clinical Research Collaboration</description>
  </link>
  <link>
    <url>https://www.cicero-copd.net/</url>
    <description>The CICERO website</description>
  </link>
  <link>
    <url>https://www.ersnet.org/research/cicero---collaboration-in-copd-exacerbations</url>
    <description>The ERS - CICERO CRC webpage</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Wim Janssens</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

